

ABSTRACT OF THE DISCLOSURE

The invention provides novel soft steroidal anti-inflammatory agents, pharmaceutical compositions containing said agents, and methods of administering same to mammals in the treatment of inflammation. Preferred  
60 compounds of the invention include haloalkyl 17 $\alpha$  alkoxy-  
62 carbonyloxy-11 $\beta$ -hydroxyandrost-4-en-3-one-17 $\beta$ -  
66 carboxylates and the corresponding  $\Delta^{1,4}$  compounds,  
60 optionally bearing 6 $\alpha$ - and/or 9 $\alpha$ -fluorine and 16 $\alpha$ - or  
10/62 16 $\beta$ -methyl substituents. Especially preferred compounds  
60 include haloalkyl 17 $\alpha$ -alkoxy-17 $\beta$ -carboxy-9 $\alpha$ -fluoro-11 $\beta$ -  
62 hydroxy-16-methylandrosta-1,4-dien-3-one-17 $\beta$ -carboxylates.